Синдром гиперандрогении у девочек пубертатного возраста

Синдром гиперандрогении у женщин - одно из самых частых заболеваний репродуктивного возраста. Ассоциация с высоким риском метаболических нарушений, сердечно-сосудистых расстройств и бесплодием определяет актуальность его изучения. В настоящий момент этиология и патогенез синдрома остаются неясными. Манифестация гиперандрогении, как правило, происходит в возрасте полового созревания. В представленном нами обзоре литературы приведены данные о течении и формировании гиперандрогении, об особенностях диагностики и лечения девочек-подростков с этим заболеванием.

синдром гиперандрогении, синдром поликистозных яичников, гирсутизм, олигоменорея, преждевременное адренархе, неклассическая форма врожденной дисфункции коры надпочечников

1. Fauser B., Eijkemans M.J. Predicting pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:9:3183-3184.

2. Futterweit W., Nestler J., Reaven G. American Association of Clinical Endocrinologists. Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract 2005;11:2:126-134.

3. Ching H.L., Burke V., Stuckey B.G. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol 2007;66:3:373-379.

4. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:1:41-47.

5. Gilling-Smith C., Willis D.S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:4:1158-1165.

6. Kumar A., Woods K.S., Bartollucci A.A., Azziz R. Prevalence of adrenal androgen excess in patients with PCOS. Clin Endocrinol (Oxford) 2005;62:6:644-649.

7. Mortensen M., Ehrmann D., Littlejohn E., Rosenfield R.L. Asymp­tomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab 2009;94:5:1579-1586.

8. Hirshfeld-Cytron J., Barnes R.B., Ehrmann D.A. et al. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:5:1587-1594.

9. Azziz R., Woods K.S., Reyna R. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:6:2745-2749.

10. Trakakis E., Basios G., Trompoukis P. et al. An update to 21-hydroxylase deficient congenital adrenal hyperplasia. Gynecol Endocrinol 2010;26:1:63-71.

11. Zawadsky J.K., Dunaf A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach / Polycystic ovary syndrome. Boston: Blackwell Scientific Publications 1992;377-384.

12. ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:1:19-25.

13. Azziz R., Carmina E., Dewailly D. et al. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete taskforse report. Fertil Steril 2009;91:2:456-488.

14. Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.

15. Balen A., Laven J.S., Tan S.L., Dewailly D. Ultrasound assessment of polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:6:505-514.

16. Escobar-Morreale H.F., Sanchon R., San Millan J.L. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008;93:2:527-533.

17. Unluhizarci K., Kula M., Dundar M. et al. The prevalence of non-classic adrenal hyperplasia among Turkish women with hyperandrogenism. Gynecol Endocrinol 2010;26:2:139-143.

18. Kuttenn F., Coullin P., Giratd F. et al. Late-onset adrenal hyperplasia in hirsutism. N Engl J Med 1985;313:4:224-231.

19. Azziz R., Zacur H.A. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab 1989;69:3:577-584.

20. Bidet M., Bellanne-Chantelot C., Galand-Portier M.B. et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009;94:5:1570-1578.

21. Lutfallah H., Wang W., Mason J.I. et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002;87:6: 2611-2622.

22. Bhattacharya S.M. Metabolic syndrome in females with polycystic ovary syndrome and international Diabetes Federation criteria. J Obstet Gynaecol Res 2008;34:1:62-66.

23. Luque-Ramez M., Alvarez-Blasco F., Mendieta-Azcona C. et al. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:6:2141-2148.

24. Deplewski D., Rosenfield R. Role of hormones in pilosebaceous unit development. Endocr Rev 2000;21:4:363-392.

25. Ciaraldi T.P., Aroda V., Mudaliar S. et al. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab 2009;94:1:157-163.

26. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:6:774-800.

27. Shah N.A., Antoine H.J., Pall M. et al. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:5:1939-1945.

28. Панфилова Е.В. Гормональные, метаболические и молекулярно-генетические аспекты синдрома гиперандрогении у девочек. М 2006.

29. Paris F., Tardy V., Chalancon A. et al. Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers. Gynecol Endocrinol 2010;26:5:319-324.

30. Cho L.W., Kilpatrick E.S., Jauagopal V. et al. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxford) 2008;68:3:390-394.

31. Stener-Victorin E., Holm G., Labrie F. et al. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab 2010;95:2:810-819.

32. Гончаров Н.П., Кация Г.В. Обзор литературы: Современные методы определения тестостерона. Вестн репрод здоровья 2008;1-2:31-37.

33. Collignon I., Porquet D. Investigation of female reproductive hormone dysfunctions. Biomeieux. France. Lyon. Brochure. 2-18.

34. Ibanez L., Dimartino-Nardi J., Potau N., Saenger P. Premature adrenarche - normal variant or forerunner of adult disease? Endocr Rev 2000;21:6:671-696.

35. Rosenfield R.L. Clinical Review: Indentifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:3:787-796.

36. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 2010;18:3:281-305.

37. Петеркова В.А., Семичева Т.В. Диагностика и лечение синдрома гиперандрогении у девочек-подростков. М 2005.

38. Fleischman A., Gordon C. Adolescent menstrual abnormalities. Pediatric Endocrinology 5th Edition. Informa Healthcare. New York (USA) 2007;2:349-360.

39. Homburg R., Lambalk C.B. Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum Reprod 2004;19:5:1039-1042.

40. Pasquali R., Antenucci D., Casmirri F. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:173-179.

41. Дедов И.И., Мельниченко Г.А., Чеботникова Т.В. и др. Половое развитие детей и подростков Московского региона: влияние ожирения. Рус мед журн 2006;14:26:1872-1877.

42. Salmi D.J., Zisser H.C., Jovanovic L. Screening for and treatment of polycystic ovary syndrome in teenagers. Exp Biol Med (Maywood) 2004;229:5:369-377.

43. James W.D. Clinical practice. Acne. N Engl J Med 2005;352:14:1463-1472.

44. Hoeger K.M., Davidson K., Kochman L. et al. J Clin Endocrinol Metab 2008;93:11:4299-4306.

45. Hoeger K.M. Exercise therapy in polycystic ovary syndrome. Semin Reprod Med 2008;26:1:93-100.

46. Ibanez L., Jaramillo A., Ferrer A., de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 2005;20:7:1833-1836.

47. Castello-Branco C., Concelo M.J. Comprehensive clinical management of hirsutism. Gynecol Endocrinol 2010;26:7:484-493.

48. Strauss J.S., Krowchuk D.P., Leyden J.J. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:4:651-663.

49. de Leo V., la Marca A., Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:5:633-667.

50. Tang T., Lord J.M., Norman R.J. et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010;1:CD003053.

51. Ibanez L., Lopez-Bermejo A., Diaz M et al. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008;93:5:1841-1845.

52. Glucophge. Final Printed Labeling. Centre for drug evaluation and research. Appl Number 2010;20-357:S019.